Archives

12 Oct

iShares Nasdaq Biotechnology ETF (IBB) Position Lifted by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC raised its stake in shares of iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 2.9% during the

11 Oct

BIO Has Big Diversity Goals. Does It Have the Means to Reach Them?

Whether from embarrassing parties or sobering surveys, the biotech gender gap problem has made plenty of headlines the past couple

11 Oct

Drug Importation: Dangerous for Patients, Consumers, and American Communities

Writing for The Hill, Steve Forbes, Forbes Media Chairman and Editor in Chief, delivered a simple message to the American

11 Oct

Bioeconomy – A new bioeconomy strategy for a sustainable Europe

[Source: Research & Innovation] Today the Commission has put forward an action plan to develop a sustainable and circular bioeconomy

11 Oct

Swabbing DNA on Phones Reveals Mysteries of Microbial World Around Us

Ask someone “What’s on your phone?” and he or she might respond with some combination of photos, music, contacts, and

10 Oct

Brent Erickson in Biofuels Digest: It’s Past Midnight in America

In 1984, President Ronald Reagan used the phrase “It’s Morning in America” as a now famous campaign message to reassure American’s

10 Oct

CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test

The FDA has lifted its hold on a clinical trial for a genetically engineered treatment for sickle cell disease, and

10 Oct

2018 Biocities Forum – 14 November 2018, Barcelona, Spain

[Source: Research & Innovation] The Biocities Forum will facilitate international science-policy-business dialogue on the potential of forests and circular bioeconomy

09 Oct

Eyeing NASH, Glympse Raises $22M to Test Disease Detection Nanotech

Glympse Bio has developed sensor technology that it says can give clinicians an early look at a developing disease. As

09 Oct

Research Headlines – Remote monitoring boost for long-term patients

[Source: Research & Innovation] Patients with long-term medical conditions, such as depression, multiple sclerosis and epilepsy, need regular monitoring, but